Investigational drug · Phase 3
SAL0120
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Kidney Disease, Uncontrolled Hypertension, Resistant Hypertension.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "SAL0120"
First trial start
2024
Oct 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SAL0120", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Kidney Disease
- Uncontrolled Hypertension
- Resistant Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Chronic kidney disease · Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "SAL0120" as an intervention, largest first.
- A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)Pivotal-lookingActive, not recruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07716618 · 320 participants (planned) · Start Jan 17, 2025 · Primary completion May 27, 2026
Drug: SAL0120 1mg; SAL0120 2mg and 2 more · For: Chronic Kidney Disease
Sites: Chengdu, China
- A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionPivotal-lookingCompleted
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07790120 · 256 participants · Start Oct 29, 2024 · Primary completion Jul 2, 2026
Drug: SAL0120; Placebo · For: Uncontrolled Hypertension; Resistant Hypertension
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Kidney Disease
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ElecoglipronPhase 39 trials
AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- lorundrostatPhase 35 trials
Mineralys Therapeutics Inc. · Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- HRS-1780Phase 33 trials
Shandong Suncadia Medicine Co., Ltd. · Chronic Kidney Disease, Uncontrolled or Resistant Hypertension, Primary Aldosteronism
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.